Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, prospective, phase 2 pilot study of bortezomib-Decp alternating with daratumumab-Vpd plus stem cell transplantation by maintenance with VP in ultra-high risk (UHiR) newly diagnosed multiple myeloma (NDMM) and primary plasma cell leukemia

Next Previous
X
Search
Trial Profile

A multicenter, prospective, phase 2 pilot study of bortezomib-Decp alternating with daratumumab-Vpd plus stem cell transplantation by maintenance with VP in ultra-high risk (UHiR) newly diagnosed multiple myeloma (NDMM) and primary plasma cell leukemia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Acronyms DRAGON CATCHER

    • Most Recent Events

    • 11 Jan 2023 New trial record
    • 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top